These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32113080)

  • 1. Current management of stage IV nasopharyngeal carcinoma without distant metastasis.
    Ng WT; Corry J; Langendijk JA; Lee AWM; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Smee R; Strojan P; Suárez C; Vermorken JB; Ferlito A
    Cancer Treat Rev; 2020 Apr; 85():101995. PubMed ID: 32113080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
    Fang FM; Huang TL; Lin YH; Chien CY; Chuang HC; Luo SD; Lin HC; Lin YT; Li SH; Liao KC; Tsai WL
    Head Neck; 2019 May; 41(5):1282-1289. PubMed ID: 30548091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma.
    Uezono H; Indelicato DJ; Rotondo RL; Sandler ES; Katzenstein HM; Dagan R; Mendenhall WM; Mailhot Vega R; Brennan BM; Bradley JA
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27990. PubMed ID: 31524334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
    Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
    Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
    Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.
    Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    BMC Cancer; 2018 Mar; 18(1):323. PubMed ID: 29580204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.
    Wang S; Li S; Shen L
    Curr Probl Cancer; 2018; 42(3):302-318. PubMed ID: 29759802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience.
    Jouin A; Helfre S; Bolle S; Claude L; Laprie A; Bogart E; Vigneron C; Potet H; Ducassou A; Claren A; Riet FG; Castex MP; Faure-Conter C; Fresneau B; Defachelles AS; Orbach D
    Strahlenther Onkol; 2019 Jun; 195(6):504-516. PubMed ID: 30963203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
    Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
    Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial.
    Cao C; Wei Q; Tang X; Jia Y; Sun X; Li W; Hu Q; Chen X
    Head Neck; 2019 May; 41(5):1427-1433. PubMed ID: 30582240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
    Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
    Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
    Li X; Zhou J; Chu C; You Q; Zhong R; Rao Z; Hu W
    Head Neck; 2019 Oct; 41(10):3525-3534. PubMed ID: 31301097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials.
    Cheng SH; Yen KL; Jian JJ; Tsai SY; Chu NM; Leu SY; Chan KY; Tan TD; Cheng JC; Hsieh CY; Huang AT
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):717-26. PubMed ID: 11395240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.